{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115538","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.237386+00:00","generated_at":"2026-06-08T11:21:11.320218+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuvectis reports Q3 2023 net loss of $5.9M; cash $22.1M; NXP800 orphan drug status","bullets":["Cash and investments $22.1M at Sep 30, 2023, up from $20.0M at Dec 31, 2022.","Net loss $5.9M for Q3 2023, unchanged YoY; R&D expenses $4.5M.","Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer ongoing; preliminary data expected Q1 2024.","NXP900 Phase 1a dose escalation initiated in advanced solid tumors; novel preclinical data presented.","FDA granted NXP800 Orphan Drug Designation for cholangiocarcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115538","json":"https://secwatch.observer/filing/0001104659-23-115538.json","markdown":"https://secwatch.observer/filing/0001104659-23-115538.md","text":"https://secwatch.observer/filing/0001104659-23-115538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923115538/0001104659-23-115538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923115538/tm2330113d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T11:21:11.320218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c46cea3ccfc9d3a3d889b6154d7c22ce609cc61","claim":"Nuvectis Pharma, Inc. reported financial results for Third Quarter 2023.","evidence_excerpt":"Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923115538/0001104659-23-115538-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Third Quarter 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}